It's Tuesday, July 7th. Welcome to Market Foolery. I'm Chris Hill with me. The one-on-only, Bill Barker.

Good to see you. Good to be here. We have another acquisition in the entertainment industry.

We have a very important investing anniversary that is coming up and we're going to

talk about that but we got to start with well essentially COVID-19 stocks and in

particular NOVA Vax and Regeneron shares of Regeneron up about 3-4 percent because Regeneron has got a

450 million dollar grant from Uncle Sam to make and supply a double antibody cocktail that's being tested against COVID-19.

And that's a nice bump for shares of Regeneron.

That pales in comparison to Novavax because those shares are up about 30% because Uncle Sam gave

Novavax, which is a biotech firm I had never heard of until today.

1.6 billion dollars to develop potential vaccine for COVID-19. This is the environment that we're in right now,

where these types of things happen,

maybe not a daily basis, but certainly on a weekly basis.

Well, in your defense, as to never having heard of Novavax before, one of the reasons might be that it's never had a drug approved or sold on the market.

And this was a company that had a stock for three or four dollars at the end of last year.

Going for a hundred and a hundred and change today.

So 25 x this year, pretty good for a company that does now have a 1.6 billion

a pile of cash or supposedly does. I think the announcement

included the information that Novavax isn't quite sure what department this money is coming from, you know.

So there's real work being done.

I don't want to diminish at all what could be an excellent opportunity to confront COVID.

But you know for a company that has really next to no sales and this is this is still more on the long shot with a high return if everything works out well

then you know the the kind of thing that you would want to bet heavily on if it were your only bet.

...